Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
Metadatos
Afficher la notice complèteAuteur
Navarro Ocón, Alba; Blaya Cánovas, José Lucas; López Tejada, Araceli; Blancas López-Barajas, María Isabel; Sánchez Martín, Rosario María; Griñán Lisón, Carmen; Calahorra, Jesús; Cara, Francisca E.; Ruiz-Cabello Osuna, Francisco; Marchal Corrales, Juan Antonio; Aptsiauri, Natalia; Granados Principal, SergioEditorial
MDPI
Materia
Breast cancer Nanomedicine Immune escape Cancer immunotherapy Cancer treatment
Date
2022-02-25Referencia bibliográfica
Navarro-Ocón, A... [et al.]. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. Pharmaceutics 2022, 14, 505. [https://doi.org/10.3390/pharmaceutics14030505]
Patrocinador
Instituto de Salud Carlos III European Commission CP14/00197 CP19/00029 PI15/00336 PI19/01533; European Regional Development Fund (European Union) Instituto de Salud Carlos III; Spanish Government; European Commission PID2020-115087GB-100 RTI2018.101309B-C22; Junta de Andalucia B-CTS-410-UGR-20; Sistema Nacional de Garantia Juvenil (Fondo Social Europeo); Fundacion Cientifica Asociacion Espanola Contra el Cancer, Junta Provincial de Jaen (AECC) PRDJA19001BLAY Spanish Government FPU19/04450; Junta de Andalucia RH-0139-2020; Junta de Andalucia, Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades DOC_01686Résumé
Breast cancer is the most common type of malignancy and leading cause of cancer death
among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy,
clinical response in breast cancer is frequently below expectations, in part due to
various mechanisms of cancer immune escape that produce tumor variants that are resistant to
treatment. Thus, a further understanding of the molecular events underlying immune evasion in
breast cancer may guarantee a significant improvement in the clinical success of immunotherapy.
Furthermore, nanomedicine provides a promising opportunity to enhance the efficacy of cancer
immunotherapy by improving the delivery, retention and release of immunostimulatory agents in
targeted cells and tumor tissues. Hence, it can be used to overcome tumor immune escape and
increase tumor rejection in numerous malignancies, including breast cancer. In this review, we
summarize the current status and emerging trends in nanomedicine-based strategies targeting cancer
immune evasion and modulating the immunosuppressive tumor microenvironment, including the
inhibition of immunosuppressive cells in the tumor area, the activation of dendritic cells and the
stimulation of the specific antitumor T-cell response.